HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Feinstein’s Cosmetics Safety Bill Launches With GOP Cosponsor

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Safety Act would preempt duplicative state-level requirements for ingredient use and manufacturer responsibilities, addressing what has become one of the foremost banes of industry in recent years, while increasing FDA’s authority over the sector and giving it new responsibilities with regard to ingredient safety review. Additional compliance requirements for industry could prove challenging, but the positive PR likely to result from the legislation could help soften the blow.

You may also be interested in...



Sen. Murray ‘Watching Closely’ For US FDA To Implement, Enforce Cosmetics Regulatory Reform

Senate HELP chair Patty Murray says she will ensure FDA implements cosmetics reform correctly and “effectively” uses enforcement tools. EWG exec says previous standards didn’t address “chronic harm caused by a known carcinogen like benzene.”

PCPC Senior Leaders Discuss Historic 2022 And What’s To Come In New Cosmetics Regulatory Era

HBW Insight spoke with the Personal Care Products Council’s Karin Ross, executive VP of government affairs, and Tom Myers, executive vice president for legal and regulatory affairs and general counsel, to discuss the Modernization of Cosmetic Regulations Act and PCPC’s role to support members’ compliance going forward.

Cosmetics Provisions Unlikely To Catch Ride On FDA User-Fee Bill

With the release of an atypically lean, clean FDA user-fee reauthorization draft bill, it’s doubtful that cosmetics regulatory reform language will get tacked onto the must-pass legislation. Stakeholders likely will refocus their efforts on standalone cosmetics legislation to modernize FDA’s oversight of the industry.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel